Reference SummaryRitland SR, Cancer Res 1997 Aug 15;57(16):3520-5
Title |
Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. | ||||||||
Authors |
Ritland SR; Rowse GJ; Chang Y; Gendler SJ | ||||||||
Journal |
Cancer Res | ||||||||
Volume |
57 | ||||||||
Issue |
16 | ||||||||
Year |
1997 | ||||||||
Pages |
3520-5 | ||||||||
Abstract |
Loss of heterozygosity (LOH) analysis has been used in many types of human cancer to localize putative tumor suppressor genes important in carcinogenesis. However, this approach has only recently been applied to transgenic mouse tumor models, which offer greater opportunity for detailed molecular genetic analysis of tumor initiation and progression. To explore the possible role of secondary genetic events in transgenic mouse mammary tumor development, we performed microsatellite-based allelotypes on primary mammary adenocarcinomas and lung metastases arising in mice transgenic for the polyomavirus middle T antigen under the control of the mouse mammary tumor virus promoter/enhancer (MMTV-MTAg mice) and on primary mammary adenocarcinomas arising in mice transgenic for the neu proto-oncogene (MMTV-neu mice). We examined a total of 80 microsatellite loci distributed throughout the mouse genome for LOH and observed high rates of specific chromosomal loss but very low rates of background allelic loss in these tumors. For the MMTV-MTAg mice, no individual chromosomes showed rates of LOH significantly above the background rates. For MMTV-neu mice, markers on chromosome 4 showed LOH in 82% of mammary tumors, whereas markers on chromosome 3 showed loss in 29% of tumors. These data suggest that the middle T antigen transgenic mice do not undergo whole chromosome loss or large genomic deletions as common mechanisms of tumor formation and that chromosomes 3 and 4 may contain tumor suppressor gene loci that play important roles in the development of neu-mediated mouse mammary tumors. | ||||||||
Links |
J:72134 – MGI References 9270023 – National Library of Medicine/PubMed |
||||||||
Strain Notes
|
|||||||||
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| STOCK Tg(MMTV-PyVT)634Mul | Mammary gland adenocarcinoma | Mammary gland |
95 |
||
| FVB/N-Tg(MMTVneu)202Mul | Mammary gland adenocarcinoma | Mammary gland |
high |
||
| B6;FVB-Tg(MMTVneu)202Mul | Mammary gland adenocarcinoma | Mammary gland |
observed |
||
| STOCK Tg(MMTVneu)202Mul | Mammary gland adenocarcinoma | Mammary gland |
observed |
||
| STOCK Tg(MMTV-PyVT)634Mul | Mammary gland hyperplasia | Mammary gland |
observed |